Gut Microbiota and Serum Metabolites in Breast Cancer Onset, Progression and Chemotherapy

A study of 295 female participants investigates the dynamic changes in gut microbiota and serum metabolites across breast cancer development and treatment. The dataset includes 16S rRNA sequencing of fecal samples and LC-MS/MS metabolomic analysis of serum samples from groups with benign breast disease, breast cancer, and post-chemotherapy breast cancer. It was authored by Shuyun Jiang and last updated on 2026-05-14.

Use Cases

• Identify microbial biomarkers for breast cancer diagnosis based on taxonomic composition shifts described in the results.
• Analyze metabolic pathway alterations associated with malignant transformation using the described nontargeted metabolomics data.
• Build predictive models for disease progression or treatment response using integrated microbiota and metabolic features.
• Study the impact of chemotherapy on the gut microbiome based on paired pre- and post-treatment samples from 24 patients.

Strengths

• Includes multiomics data from 295 participants across three clinical groups (BBD n=83, BC n=100, PCBC n=88).
• Contains longitudinal data with 24 paired fecal samples collected before and after chemotherapy.
• Nontargeted metabolomics analysis revealed more than 3,000 metabolites, as stated in the description.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 14.6 KB file size suggests the uploaded document is likely a summary or manuscript, not the raw underlying data tables.

Provenance

Source

figshare

Collection Method

Clinical study involving 16S rRNA sequencing and LC-MS/MS metabolomic analysis.

Freshness

Last updated 2026-05-14 04:24:14; freshness should be verified.